Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).

ODM-208, an oral, selective inhibitor of CYP11A1, is being evaluated for safety and eficacy as a treatment of mCRPC in the ongoing CYPI-DES phase I/II trial in men previously treated with both novel hormonal therapies and taxanes (Clinical-Trials.gov identifier: NCT03436485).

• Opevesostat (MK-5684; ODM-208) is an oral nonsteroidal inhibitor of cytochrome P450 11A1 (CYP11A1), which catalyzes the first and rate-limiting step of steroid biosynthesis from cholesterol 5,6

• Opevesostat (MK-5684; ODM-208) is an oral nonsteroidal inhibitor of cytochrome P450 11A1 (CYP11A1) that catalyzes the first and rate-limiting step of steroid biosynthesis from cholesterol – Inhibition of CYP11A1 by opevesostat can potentially suppress the production of all steroid hormones and precursors that may activate the AR

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.

Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). - ASCO.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Professor Karim Fizazi presented updated results of the phase II CYPIDES trial of opevesostat (ODM-208/MK-5684), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate ...

Data from the Phase II CYPIDES trial suggest that ODM-208/MK-5684 potently inhibits all steroid-hormone biosynthesis with observed antitumor activity in a heavily pretreated mCRPC population, especially in patients with AR-LBD mutations.

Poster session 10 1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results Date

Background: MK-5684 (previously ODM-208) is a first-in-class, oral, non-steroidal, selective inhibitor of CYP11A1, the first and rate-limiting enzyme of steroid biosynthesis. MK-5684 suppresses the production of all steroid hormones and precursors that may activate the androgen receptor (AR) signaling pathway.